<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01066026</url>
  </required_header>
  <id_info>
    <org_study_id>08-CBED08-02</org_study_id>
    <nct_id>NCT01066026</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of a Metallic Cannula Versus A Standard Needle for Soft Tissue Augmentation of the Nasolabial Folds</brief_title>
  <official_title>Double-blind, Randomized and Controlled Clinical Trial to Compare Safety and Efficacy of a Metallic Cannula vs a Standard Needle for the Injection of Hyaluronic Acid Gel Dermal Filler (Restylane速) to Treat Nasolabial Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brazilan Center for Studies in Dermatology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brazilan Center for Studies in Dermatology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess the safety and efficacy of a new metallic cannula to&#xD;
      inject hyaluronic acid for dermal augmentation in the nasolabial folds compared to standard&#xD;
      needle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a monocentric, prospective, randomized, phase II and double-blind study.&#xD;
&#xD;
      At the baseline visits, one investigator rated the severity of nasolabial folds on both left&#xD;
      and right sides according to the mentioned scale, and a standard set of six photographs of&#xD;
      the face (frontal, left side and right side for both the whole face and the lower face) were&#xD;
      taken.&#xD;
&#xD;
      On the day of the injection, the main investigator injected 1ml of dermal filler - hyaluronic&#xD;
      acid (Restylane速, Q-Med, Uppsala, Sweden) - for each subject. The injected amount was 0,5ml&#xD;
      for the right nasolabial fold and 0,5ml for the left nasolabial fold. The sides will be&#xD;
      randomized.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Haematoma</measure>
    <time_frame>Day 1; day 3; day 7; day 90</time_frame>
    <description>Number of participants with haematoma at each visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Erythema</measure>
    <time_frame>Day 1; day 3; day 7; day 90</time_frame>
    <description>Number of participants with erythema at each visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Fitzpatrick Wrinkle Scale (MFWS)</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <description>Class 0 - No visible wrinkles; continuous skin lines Class 0.5 - Very shallow yet visible wrinkles Class 1 - Fine wrinkles. Visible wrinkles and slight indentations Class 1.5 - Visible wrinkles and clear indentations,&lt;1-mm wrinkle depth* Class 2 - Moderate wrinkles. Clearly visible wrinkles, 1- to 2-mm wrinkle depth* Class 2.5 - Prominent and visible wrinkles; 2- to 3-mm wrinkle depth* Class 3 - Deep wrinkles. Deep, furrowed wrinkle; *&gt;3-mm wrinkle depth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Aesthetic Improvement Scale</measure>
    <time_frame>90 days</time_frame>
    <description>Very much improved: Optimal cosmetic result for the implant in this patient&#xD;
Much improved: Marked improvement in appearance from the initial condition but not completely optimal for this patient; touch-up would slightly improve the result&#xD;
3 - Improved: Obvious improvement in appearance from the initial condition, but touch-up or retreatment is indicated&#xD;
4 - No change: Appearance essentially the same as the original condition&#xD;
5 - Worse: Appearance worse than the original condition</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Wrinkles</condition>
  <arm_group>
    <arm_group_label>Metallic cannula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasolabial Fold with metallic cannula and hyaluronic acid injected. hyaluronic acid with metallic cannula or standard needle. Hyaluronic acid injected with the new tool</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard needle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nasolabial Fold with standard needle and hyaluronic acid injected. hyaluronic acid with metallic cannula or standard needle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hyaluronic acid with metallic cannula or standard needle.</intervention_name>
    <description>The sides of injection were randomized and both the subject and the evaluator were blind to it. The injections were performed according through two different devices:&#xD;
In one of the sides, the hyaluronic acid (Restylane速) was injected in its conventional pharmaceutical presentation, with a standard needle which is part of the product's kit;&#xD;
In the other side, the hyaluronic acid (Restylane速) was injected through a metallic cannula, which replaced the needle of the product's kit.&#xD;
Local analgesia was provided for both applications: topical analgesics 4% Lidocaine, for the application with the standard needle, and nerve block (Lidocaine 2%), where the application was performed with the metallic cannula.</description>
    <arm_group_label>Metallic cannula</arm_group_label>
    <arm_group_label>Standard needle</arm_group_label>
    <other_name>Restylane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyaluronic acid injected with the new tool.</intervention_name>
    <description>hyaluronic acid with metallic cannula.</description>
    <arm_group_label>Metallic cannula</arm_group_label>
    <other_name>Restylane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects agreeing to take part of the study, after being fully informed of the purpose&#xD;
             and the nature of the investigation and after having signed the informed consent form&#xD;
&#xD;
          -  Female subjects aged from 18 to 60&#xD;
&#xD;
          -  Fitzpatrick phototype I to VI&#xD;
&#xD;
          -  Presence of bilateral folds graded from 2 to 3 according to the Modified&#xD;
&#xD;
          -  Fitzpatrick Wrinkle Scale&#xD;
&#xD;
          -  Subjects that have never performed any treatment of nasolabial folds&#xD;
&#xD;
          -  Female subjects of childbearing age that present a negative urine pregnancy test and&#xD;
             are using an effective contraceptive method&#xD;
&#xD;
          -  Subjects who will be available throughout the duration of the study&#xD;
&#xD;
          -  Subjects with sufficient schooling and awareness to enable them to cooperate to the&#xD;
             degree required by this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of systemic corticosteroids&#xD;
&#xD;
          -  History of herpes in lip&#xD;
&#xD;
          -  Inflammation or active infection in the area to be injected&#xD;
&#xD;
          -  Any surgical treatment or cosmetic procedure in the area to be injected that interfere&#xD;
             in study's outcomes&#xD;
&#xD;
          -  Coagulation disorders or use of anticoagulants&#xD;
&#xD;
          -  Previous hypersensitivity responses to Hyaluronic acid.&#xD;
&#xD;
          -  Pregnant or women in breastfeeding, or women planning to become pregnant&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doris Hesxel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CBED</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brazilian Center for Studies in Dermatology</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90570-040</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Brasileiro de Estudos em Dermatologia</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 26, 2010</study_first_submitted>
  <study_first_submitted_qc>February 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2010</study_first_posted>
  <results_first_submitted>February 22, 2012</results_first_submitted>
  <results_first_submitted_qc>August 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 9, 2020</results_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brazilan Center for Studies in Dermatology</investigator_affiliation>
    <investigator_full_name>Doris Hexsel</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>metallic cannula</keyword>
  <keyword>Hyaluronic acid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metallic Cannula</title>
          <description>Standard needle and metallic cannula were used in the same patient, with split face.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25">Each patient was injected with hyaluronic acid in each nasolabial fold (total: 2 injections)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metallic Cannula and Standart Cannula</title>
          <description>Nasolabial Folds received fullers with Metallic Cannula or with Standard Needle</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Haematoma</title>
        <description>Number of participants with haematoma at each visit</description>
        <time_frame>Day 1; day 3; day 7; day 90</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metallic Cannula</title>
            <description>Split face; metallic cannula on one side of the face and standard needle on the contralateral side (same patient).</description>
          </group>
          <group group_id="O2">
            <title>Standard Needle</title>
            <description>Split face; metallic cannula on one side of the face and standard needle on the contralateral side (same patient).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Haematoma</title>
          <description>Number of participants with haematoma at each visit</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence (legacy)</non_inferiority_type>
            <non_inferiority_desc>pilot study.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>McNemar</method>
            <param_type>descritive variables</param_type>
            <param_value>50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5</ci_lower_limit>
            <ci_upper_limit>95</ci_upper_limit>
            <estimate_desc>50 was the percentage of hematomas expected for standard needle group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Erythema</title>
        <description>Number of participants with erythema at each visit</description>
        <time_frame>Day 1; day 3; day 7; day 90</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metallic Cannula</title>
            <description>Split face; metallic cannula on one side of the face and standard needle on the contralateral side (same patient).</description>
          </group>
          <group group_id="O2">
            <title>Standard Needle</title>
            <description>Split face; metallic cannula on one side of the face and standard needle on the contralateral side (same patient).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Erythema</title>
          <description>Number of participants with erythema at each visit</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Fitzpatrick Wrinkle Scale (MFWS)</title>
        <description>Class 0 - No visible wrinkles; continuous skin lines Class 0.5 - Very shallow yet visible wrinkles Class 1 - Fine wrinkles. Visible wrinkles and slight indentations Class 1.5 - Visible wrinkles and clear indentations,&lt;1-mm wrinkle depth* Class 2 - Moderate wrinkles. Clearly visible wrinkles, 1- to 2-mm wrinkle depth* Class 2.5 - Prominent and visible wrinkles; 2- to 3-mm wrinkle depth* Class 3 - Deep wrinkles. Deep, furrowed wrinkle; *&gt;3-mm wrinkle depth</description>
        <time_frame>Baseline and 90 days</time_frame>
        <population>Per protocol analysis. 23 participants attended to visit &quot;Day 90'.</population>
        <group_list>
          <group group_id="O1">
            <title>Metallic Cannula</title>
            <description>Split face; metallic cannula on one side of the face and standard needle on the contralateral side (same patient).</description>
          </group>
          <group group_id="O2">
            <title>Standard Needle</title>
            <description>Split face; metallic cannula on one side of the face and standard needle on the contralateral side (same patient).</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Fitzpatrick Wrinkle Scale (MFWS)</title>
          <description>Class 0 - No visible wrinkles; continuous skin lines Class 0.5 - Very shallow yet visible wrinkles Class 1 - Fine wrinkles. Visible wrinkles and slight indentations Class 1.5 - Visible wrinkles and clear indentations,&lt;1-mm wrinkle depth* Class 2 - Moderate wrinkles. Clearly visible wrinkles, 1- to 2-mm wrinkle depth* Class 2.5 - Prominent and visible wrinkles; 2- to 3-mm wrinkle depth* Class 3 - Deep wrinkles. Deep, furrowed wrinkle; *&gt;3-mm wrinkle depth</description>
          <population>Per protocol analysis. 23 participants attended to visit &quot;Day 90'.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="0.37"/>
                    <measurement group_id="O2" value="2.40" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="0.57"/>
                    <measurement group_id="O2" value="1.54" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Aesthetic Improvement Scale</title>
        <description>Very much improved: Optimal cosmetic result for the implant in this patient&#xD;
Much improved: Marked improvement in appearance from the initial condition but not completely optimal for this patient; touch-up would slightly improve the result&#xD;
3 - Improved: Obvious improvement in appearance from the initial condition, but touch-up or retreatment is indicated&#xD;
4 - No change: Appearance essentially the same as the original condition&#xD;
5 - Worse: Appearance worse than the original condition</description>
        <time_frame>90 days</time_frame>
        <population>Per protocol analysis. 23 participants attended to visit &quot;Day 90'.</population>
        <group_list>
          <group group_id="O1">
            <title>Metallic Cannula</title>
            <description>Split face; metallic cannula on one side of the face and standard needle on the contralateral side (same patient).</description>
          </group>
          <group group_id="O2">
            <title>Standard Needle</title>
            <description>Split face; metallic cannula on one side of the face and standard needle on the contralateral side (same patient).</description>
          </group>
        </group_list>
        <measure>
          <title>Global Aesthetic Improvement Scale</title>
          <description>Very much improved: Optimal cosmetic result for the implant in this patient&#xD;
Much improved: Marked improvement in appearance from the initial condition but not completely optimal for this patient; touch-up would slightly improve the result&#xD;
3 - Improved: Obvious improvement in appearance from the initial condition, but touch-up or retreatment is indicated&#xD;
4 - No change: Appearance essentially the same as the original condition&#xD;
5 - Worse: Appearance worse than the original condition</description>
          <population>Per protocol analysis. 23 participants attended to visit &quot;Day 90'.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="0.6"/>
                    <measurement group_id="O2" value="2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <desc>pain,</desc>
      <group_list>
        <group group_id="E1">
          <title>Metallic Cannula</title>
          <description>Nasolabial Fold with Metallic Cannula</description>
        </group>
        <group group_id="E2">
          <title>Standard Needle</title>
          <description>Nasolabial Fold with standard needle</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Doris Hexsel</name_or_title>
      <organization>Brazilian Center for Studies in Dermatology</organization>
      <phone>55 51 30262633</phone>
      <email>cientifico@cbed.org.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

